Key Transaction Details

  • Acquirer: Mr. Swapan Khandelwal, Promoter and Whole Time Director of Goldline Pharmaceutical Limited
  • DIN: 03486882
  • Number of shares acquired: 60,000 equity shares
  • Percentage of total issued and paid-up share capital: 0.62%
  • Mode of acquisition: Open market purchase
  • Date of acquisition: 22nd June, 2026
  • Disclosure date: 23rd June, 2026

Shareholding Changes

Before Acquisition (as of pre-June 22, 2026):

  • Shares carrying voting rights: 2,749,988
  • Percentage of total voting capital: 28.65%
  • No shares encumbered (pledge/lien/non-disposal undertaking)
  • No voting rights otherwise than by equity shares
  • No warrants/convertible securities/other instruments
  • Total holding: 2,749,988 shares (28.65%)

Acquisition Details:

  • Shares acquired: 60,000
  • Percentage of total voting capital: 0.62%
  • No other instruments or encumbrances involved
  • Total acquisition: 60,000 shares (0.62%)

After Acquisition (as of June 22, 2026):

  • Shares carrying voting rights: 2,809,988
  • Percentage of total voting capital: 29.27%
  • No shares encumbered
  • No voting rights otherwise than by equity shares
  • No warrants/convertible securities/other instruments
  • Total holding: 2,809,988 shares (29.27%)

Capital Structure Impact

  • Equity share capital before acquisition: 9,600,000 equity shares
  • Equity share capital after acquisition: 9,600,000 equity shares (no change in total capital)
  • Total diluted share/voting capital: Nil